The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact). Common warts have a characteristic cauliflower-like surface, are typically slightly raised above the surrounding skin and are generally diagnosed by visual inspection.The treatment of warts poses a therapeutic challenge for physicians. No single therapy has been proven effective at achieving complete remission in every patient.This study will aim to evaluate an up-to a three-day course of therapy with 0.05% PEP005 Topical Gel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study With a Topical Gel to Treat Common Warts in Adults

NCT00117871

Warts

COMPLETED PHASE2

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00115141

Warts

COMPLETED PHASE2

The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts

NCT03477448

Warts

UNKNOWN PHASE4

Study With a Topical Gel to Treat Common Warts in Adults

NCT00117923

Warts

COMPLETED PHASE2

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

NCT01532102

Anogenital Warts Condylomata Acuminata Human Papillomavirus Infection

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Warts

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.

Group Type ACTIVE_COMPARATOR

PEP005

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PEP005

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients at least 18 years of age.
* A clinically diagnosed, single common cutaneous viral wart (verruca vulgaris) on the dorsal hand.
* Written informed consent has been obtained.
* Agreement from the patient to allow photographs of the common wart(s) treatment area to be taken and used as part of the study package.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No